OakChart

Protalix BioTherapeutics Inc

PLXHealthcare·Biotechnology·USA·Micro·AMEX·Nov 11 • 3:59 PM ET

3.13+0.27 (9.44%)
2026-11-11 22:31 CET
Market cap
230.43 USD m
Revenue, TTM
84.69 USD m
Net income, TTM
20.55 USD m
Free cash flow, TTM
15.06 USD m
EPS diluted, TTM
0.25
P/E
12.76
Compare

Price

PLX against its 20, 50 and 200-day averages
2050200beatearnings
2.002.503.001.5M3.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PLXclose 3.1320-day 2.6250-day 2.67200-day 2.443.13

1.9% under the 52-week high of 3.19 on 23 Feb 2026. 52-week low 1.65 on 2 Dec 2025. Last 15 sessions, 28.2% high to low

Volume 3.79× normal · the line is the 50-bar volume average

Profile

PLX
52-week range, 96% of the way up
1.653.19

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

IndexRUT
Employees226
IPOApr 09, 1996
Beta-0.03
ATR, 14d0.15
Rel volume3.79
Short float4.75%
Insider own9.04%
Inst own20.91%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap252.18M
Enterprise Value212.05M
Income20.55M
Sales84.69M
Book/sh0.98
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees226
IPOApr 09, 1996

Ratios

P/E12.76
Forward P/E34.78
PEG-
P/S2.98
P/B3.21
P/C5.12
P/FCF16.75
EV/EBITDA7.91
EV/Sales2.50
Quick Ratio2.14
Current Ratio3.27
Debt/Eq0.11
LT Debt/Eq0.09
Option/ShortYes / Yes

Earnings

EPS (ttm)0.25
EPS next Y0.09
EPS next Q-0.04
EPS this Y393.75%
EPS next Y-61.70%
EPS next 5Y-
EPS past 3/5Y35.12% 17.78%
Sales past 3/5Y3.45% -3.46%
EPS Y/Y TTM266.67%
Sales Y/Y TTM36.96%
EPS Q/Q62.89%
Sales Q/Q22.82%
EarningsNov 10 BMO
EPS/Sales Surpr.350.00% 76.53%

Ownership

Insider Own9.04%
Insider Trans0.00%
Inst Own20.91%
Inst Trans2.66%
ROA20.50%
ROE30.80%
ROIC23.35%
Gross Margin71.21%
Oper. Margin29.76%
Profit Margin24.27%
SMA2019.28%
SMA5017.04%
SMA20028.37%
Trades-

Technical

Shs Outstand82.49M
Shs Float73.29M
Short Float4.75%
Short Ratio4.27
Short Interest3.48M
52W High3.19 -1.88%
52W Low1.65 89.70%
Volatility8.42% 4.88%
ATR (14)0.15
RSI (14)71.22
Beta-0.03
Rel Volume3.79
Avg Volume815.60K
Volume3,090,230

Performance

Perf Week16.36%
Perf Month13.82%
Perf Quarter32.63%
Perf Half Y62.18%
Perf YTD73.89%
Perf Year46.95%
Perf 3Y133.58%
Perf 5Y184.55%
Perf 10Y-35.06%
Recom1.00
Target Price11.00
Prev Close2.86
Price3.13
Change %9.44%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Jun 08, 2020ReiteratedHH.C. WainwrightBuy$3 → $11+251.4%
Apr 17, 2017ReiteratedRRodman & RenshawBuy$4 → $5+59.7%
Apr 04, 2016InitiatedRRodman & RenshawBuy$3.50+11.8%
Apr 23, 2015UpgradeJJefferiesHold → Buy$2 → $2.60-16.9%
Nov 12, 2014ReiteratedRR. F. LaffertyBuy$8 → $5+59.7%
Jan 24, 2014InitiatedRR. F. LaffertyBuy$8+155.6%
May 02, 2012ReiteratedOOppenheimerOutperform$9 → $11+251.4%
May 02, 2012DowngradeCCanaccord GenuityBuy → Hold$8 → $8+155.6%
Apr 30, 2012DowngradeAAurigaBuy → Hold$8 → $8+155.6%
Oct 13, 2011InitiatedMMorgan JosephHold

Peers

Mkt cap
TickerCompanyMkt cap
BMRNBiomarin Pharmaceutical Inc11.30B
SNYSanofi ADR115.43B
FDMT4D Molecular Therapeutics Inc717.62M
PHARPharming Group NV ADR948.45M
RAREUltragenyx Pharmaceutical Inc1.70B
TAKTakeda Pharmaceutical Co ADR66.58B
CDXSCodexis Inc106.93M
DNLIDenali Therapeutics Inc3.16B
AMGNAMGEN Inc253.21B
PFEPfizer Inc167.86B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bashan DrorPRESIDENT AND CEODec 19 '25Buy1.8156,000101,360188,516Dec 23 07:25 AM
Bar-Shalev AmosDirectorNov 18 '25Sale1.871683140Nov 19 04:34 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
EESWisdomTree U.S. SmallCap FundAUM: 684.87M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-100.050-0.0200.05021.9312.422
2026Q22026-08-120.050-0.0100.04619.9012.952
2026Q12026-05-130.220-0.0100.22133.7511.501
2025Q42026-03-18-0.0600.040-0.0689.1218.301
2025Q32025-11-130.0300.0550.02917.8517.892
2025Q22025-08-140.0000.0400.00215.6615.531
2025Q12025-05-09-0.0500.080-0.04710.1121.601
2024Q42025-03-170.1000.0700.08618.2218.752
2024Q32024-11-140.0300.0600.03417.9616.261
2024Q22024-08-14-0.0300.020-0.03013.4712.501
2024Q12024-05-10-0.060--0.0633.75--
2023Q42024-03-14-0.030-0.025-0.08310.478.152
2023Q32023-11-06-0.040-0.070-0.04310.357.652
2023Q22023-08-070.210-0.0400.21135.0810.201
2023Q12023-05-04-0.050--0.0559.59--
2022Q42023-02-27-0.080-0.150-0.0738.626.121

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-3.600-4.500-6.36519.2427.76
2018FY-1.800-2.900-1.7988.9818.60
2019FY-1.230-1.880-1.23254.6947.20
2020FY-0.220-0.335-0.22462.9055.31
2021FY-0.620-0.590-0.62538.3537.59
2022FY-0.310-0.390-0.30847.6445.14
2023FY0.0900.1050.08765.4963.95
2024FY0.0400.0150.03753.4053.94
2025FY-0.0800.030-0.08052.7462.00
2026FY-0.235--83.33
2027FY-0.090--71.81
2028FY-0.020--68.82

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1020112.859.5016.20
2026Q4S2026-11-0220016.1016.0016.20
2026Q4S2026-10-2620016.1116.0116.20
2026Q4S2026-09-0820116.1116.0116.20
2026Q4S2026-09-0210116.2016.2016.20
2026Q4S2026-08-1220116.1016.0016.20
2026Q4S2026-08-0520016.7516.0017.50
2026Q4S2026-05-2521016.7516.0017.50
2026Q4S2026-05-2221016.7516.0117.50
2026Q4S2026-05-1320116.3515.2017.50
2026Q4S2026-03-1810115.2015.2015.20
2026Q4S2026-02-0310020.9020.9020.90
2026Q4S2025-11-2010120.9020.9020.90
2026Q4S2025-11-1310026.7026.7026.70

Estimate history

EPS, annual-6.365-1.798-1.232-0.224-0.625-0.3080.0870.037-0.0840.2453
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0340.086-0.0470.0020.029-0.0680.2210.0460.047
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual21.07834.2454.69362.89838.3547.63865.49453.39952.74484.69
Period201720182019202020212022202320242025TTM
Sales, quarterly17.95918.21810.11315.65817.8519.12233.7519.89621.925
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual14.37314.83814.83834.76545.55753.7972.95275.8580.42682.493
Period201720182019202020212022202320242025MRQ
Shares, quarterly73.63475.8578.13479.73280.34180.42680.57280.57282.493
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue84.6952.7453.4065.4947.6438.3562.9054.6934.24
Cost of Goods Sold Incl. D&A24.3827.5124.3222.9819.5916.3510.8710.899.30
Gross Profit60.3125.2429.0842.5128.0522.0052.0243.8024.94
Selling, General and Administrative Excl. Other35.1030.7425.1632.0541.0642.4649.3154.5946.45
Research and Development22.3419.0512.9717.0929.3529.7338.1744.6935.53
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income25.21-5.503.9210.46-13.01-20.462.71-10.79-21.51
Interest Expense1.091.191.063.182.537.529.677.977.68
Unusual Expense0.000.000.000.000.000.000.000.00-
Net Income Before Taxes25.85-5.614.158.57-14.40-27.58-6.52-18.28-26.46
Income Taxes5.301.001.220.250.530.000.000.000.00
Consolidated Net Income20.55-6.602.938.31-14.93-27.58-6.52-18.28-26.46
Net Income From Continuing Operations20.55-6.602.938.31-14.93-27.58-6.52-18.28-26.46
Net Income20.55-6.602.938.31-14.93-27.58-6.52-18.28-26.46
EPS (Recurring)0.25-0.080.040.09-0.31-0.62-0.22-1.23-1.80
EPS (Basic, Before Extraordinaries)0.26-0.080.040.12-0.31-0.62-0.22-1.23-1.80
EPS (Diluted)0.25-0.080.040.09-0.31-0.62-0.22-1.23-1.80
EBITDA26.82-4.045.2211.65-11.93-19.344.01-9.18-19.84
Non-Operating Income (Expense)1.731.081.301.291.150.400.440.482.74
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.011.812.572.721.652.383.130.830.51
Price To Earnings Ratio11.6611.66-43.52-----
Price To Sales Ratio2.722.682.852.241.390.961.680.891.34
Gross Margin71.2147.8554.4664.9158.8757.3782.7180.0872.83
Operating Margin29.76-10.437.3415.97-27.32-53.364.31-19.74-62.83
Net Margin24.27-12.525.4912.69-31.33-71.92-10.37-33.42-77.27
Shares Outstanding82.4980.4375.8572.9553.7945.5634.7714.8414.84
Market Capitalization230.43230.43138.43129.8569.4137.89121.0148.6746.15

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue21.9319.9033.759.1217.8515.6610.1118.22
Cost of Goods Sold Incl. D&A7.887.764.134.628.325.878.183.89
Gross Profit14.0512.1329.624.509.539.791.9314.33
Selling, General and Administrative Excl. Other10.007.468.489.167.408.626.087.12
Research and Development6.924.355.435.634.475.993.484.12
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income4.054.6721.15-4.662.131.17-4.147.21
Interest Expense0.020.490.190.380.180.780.010.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes4.624.8621.14-4.782.240.66-3.737.32
Income Taxes0.661.082.820.73-0.120.50-0.110.82
Consolidated Net Income3.963.7818.32-5.502.350.16-3.626.49
Net Income From Continuing Operations3.963.7818.32-5.502.350.16-3.626.49
Net Income3.963.7818.32-5.502.350.16-3.626.49
EPS (Recurring)0.050.050.22-0.070.030.00-0.050.09
EPS (Basic, Before Extraordinaries)0.050.050.23-0.070.030.00-0.050.09
EPS (Diluted)0.050.050.22-0.070.030.00-0.050.09
EBITDA4.475.0821.55-4.272.501.53-3.807.54
Non-Operating Income (Expense)0.600.680.190.270.290.270.420.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.700.310.420.580.470.340.430.52
Price To Earnings Ratio11.6610.2611.8425.9030.0035.2497.34-
Price To Sales Ratio2.722.392.362.742.901.943.282.67
Gross Margin64.0860.9987.7749.3653.3762.5119.1178.67
Operating Margin18.4623.4862.65-51.0611.947.48-40.9939.57
Net Margin18.0718.9854.27-60.3413.191.05-35.7935.65
Shares Outstanding82.4980.5780.5780.4380.3479.7378.1375.85
Market Capitalization230.43187.73174.84144.76177.01117.82199.76138.43

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments30.9834.8344.5622.1838.9838.9818.6138.3751.79
Short Term Receivables8.842.915.274.593.442.004.704.731.72
Inventories25.7321.2419.0516.8017.9513.088.158.577.83
Other Current Assets1.131.101.051.311.281.661.011.321.31
Total Current Assets66.6760.0869.9344.8861.6755.7232.4852.9862.65
Net Property, Plant & Equipment12.5810.0210.889.649.9210.4110.956.397.68
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets2.522.863.09------
Other Assets0.580.460.531.272.081.801.961.761.89
Total Assets82.3573.4284.4355.7973.6767.9345.3961.1372.21
Short Term Debt Incl. Current Port. of LT Debt1.381.5021.661.121.2159.935.440.005.92
Accounts Payable5.264.534.325.866.997.226.505.217.52
Income Tax Payable2.953.482.88------
Other Current Liabilities16.9316.1116.6725.4524.9819.3228.2420.149.31
Total Current Liabilities26.5225.6245.5332.4333.1886.4740.1725.3522.75
Long Term Debt6.944.034.6232.3632.264.4755.4847.9746.27
Provision for Risks Charges0.660.560.711.642.472.262.562.372.59
Other Liabilities0.000.000.000.0011.791.7717.4938.3230.07
Total Liabilities34.1230.2150.8766.4379.7094.97115.71114.01101.67
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity48.2343.2133.57-10.64-6.04-27.04-70.32-52.88-29.46
Total Shareholders Equity48.2343.2133.57-10.64-6.04-27.04-70.32-52.88-29.46
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity48.2343.2133.57-10.64-6.04-27.04-70.32-52.88-29.46
Total Liabilities & Stockholders Equity82.3573.4284.4355.7973.6767.9345.3961.1372.21
Book Value Per Share0.600.570.46-0.20-0.13-0.78-4.74-3.56-2.05
Tangible Book Value Per Share0.600.570.46-0.20-0.13-0.78-4.74-3.56-2.05
Full-Time Employees226213208197206207196184190
Price to Book Ratio2.934.273.40-5.97177.71-4.67-0.69-0.87-3.39
Return on Assets-8.483.7111.86-23.06-38.96-11.51-34.31-39.68-108.04
Return on Equity-14.447.6472.50------
Return on Invested Capital-11.976.2121.76-68.74-105.17----496.37
Quick Ratio1.541.521.120.871.320.490.611.752.41
Current Ratio2.512.341.541.381.860.640.812.092.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income20.55-6.602.938.31-14.93-27.58-6.52-18.28-26.46
Depreciation1.621.471.301.191.091.121.301.621.67
Other Funds (Non Cash)2.872.903.39-0.280.866.286.254.143.52
Funds from Operations25.42-1.897.869.22-12.98-20.191.02-12.52-21.27
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-7.86-10.100.81-10.54-12.029.90-27.13-6.8313.53
Cash from Operating Activities17.56-11.998.67-1.32-25.00-10.29-26.11-19.36-7.74
Capital Expenditures-2.49-1.64-1.28-1.15-0.63-1.46-0.66-0.63-0.69
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.050.000.00-
Purchase or Sale of Investments-24.79-0.700.000.000.000.000.000.000.00
Purchase of Investments-24.79-0.700.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-5.02-5.00-15.00-20.56-15.41-37.94-20.000.000.00
Other Sources17.974.9720.505.0011.0058.270.700.000.03
Cash from Investing Activities-14.34-2.374.22-16.71-5.0418.92-19.95-0.62-0.65
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.889.333.6324.678.2446.2046.680.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.889.333.6324.678.2446.2046.680.000.00
Proceedsfrom Stock Options4.216.813.630.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.00-20.420.000.00-34.12-0.210.00-4.75
Change in Long Term Debt0.000.00-20.420.000.00-34.12-0.210.00-4.75
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-20.420.000.00-34.12-0.210.00-4.75
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities4.889.33-16.7924.678.2412.0846.470.00-4.75
Exchange Rate Effect0.28-0.050.03-0.11-0.080.010.060.23-0.27
Net Change in Cash8.39-5.08-3.876.52-21.8720.720.47-19.76-13.42
Free Cash Flow15.06-13.637.39-2.47-25.63-11.74-26.76-19.98-8.43
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow15.31-20.62------
Deferred Taxes & Investment Tax Credit-0.340.240.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments49.2741.3851.7930.9829.3733.40
Short Term Receivables13.9116.502.948.8414.439.44
Inventories34.3032.2930.4725.7321.2521.13
Other Current Assets1.402.051.151.131.451.51
Total Current Assets98.8792.2286.3666.6766.5065.48
Net Property, Plant & Equipment14.0413.6412.9512.5812.539.74
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets2.302.372.442.522.682.74
Other Assets0.000.000.590.580.550.52
Total Assets118.24110.34102.3482.3582.2678.49
Short Term Debt Incl. Current Port. of LT Debt1.691.671.431.381.401.47
Accounts Payable4.786.514.295.265.386.69
Income Tax Payable2.944.213.202.952.383.74
Other Current Liabilities20.8319.0018.4716.9312.7912.19
Total Current Liabilities30.2331.3927.3926.5221.9524.09
Long Term Debt7.467.547.056.946.783.88
Provision for Risks Charges0.000.000.670.660.630.61
Other Liabilities0.000.000.000.000.000.00
Total Liabilities37.6938.9335.1134.1229.3628.58
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity80.5571.4067.2348.2352.9149.90
Total Shareholders Equity80.5571.4067.2348.2352.9149.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity80.5571.4067.2348.2352.9149.90
Total Liabilities & Stockholders Equity118.24110.34102.3482.3582.2678.49
Book Value Per Share0.980.890.830.600.660.63
Tangible Book Value Per Share0.980.890.830.600.660.63
Full-Time Employees---226--
Price to Book Ratio2.932.632.602.733.552.56
Return on Assets20.5020.0717.40-8.487.507.38
Return on Equity30.8031.2327.27-14.4412.6415.99
Return on Invested Capital4.504.7824.66-9.983.950.30
Quick Ratio2.141.912.041.542.061.84
Current Ratio3.272.943.152.513.032.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income3.963.7818.32-5.502.350.16
Depreciation0.420.410.400.390.370.36
Other Funds (Non Cash)0.060.910.691.210.620.91
Funds from Operations4.525.1619.49-3.753.401.67
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.61-15.562.545.78-7.14-6.90
Cash from Operating Activities3.90-10.4022.022.03-3.73-5.23
Capital Expenditures-0.74-0.59-0.76-0.40-0.50-0.43
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-16.07-3.01-5.01-0.700.000.00
Purchase of Investments-16.07-3.01-5.01-0.700.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.00-0.03-0.01-4.98-0.01-0.01
Other Sources3.000.0010.004.970.000.00
Cash from Investing Activities-13.81-3.634.22-1.11-0.50-0.44
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.580.000.150.150.004.10
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.580.000.150.150.004.10
Proceedsfrom Stock Options4.210.000.000.000.003.95
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.580.000.150.150.004.10
Exchange Rate Effect-0.060.45-0.08-0.03-0.010.00
Net Change in Cash-5.38-13.5826.321.03-4.25-1.56
Free Cash Flow3.17-10.9921.261.63-4.23-5.66
Price to Free Cash Flow15.3125.0913.87---

Revenue breakdown

License and Service2024: 418.00K 2025: 942.00K
Product2024: 52.98M 2025: 51.80M
United States2024: 53.40M 2025: 52.74M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.75%3.5M73.3M792.38K
2026-10-154.79%3.5M73.3M774.24K
2026-09-303.93%3.0M77.5M690.82K
2026-09-153.72%2.9M77.5M713.17K
2026-08-314.09%3.2M77.5M679.25K
2026-08-144.62%3.6M77.5M705.24K
2026-07-315.01%3.9M77.5M722.29K
2026-07-154.80%3.7M77.5M725.34K
2026-06-304.60%3.6M77.5M752.10K
2026-06-155.05%3.9M77.5M817.80K
2026-05-295.08%3.9M77.5M888.88K
2026-05-155.40%4.2M77.5M990.18K
2026-04-307.02%5.1M72.1M1.17M
2026-04-156.56%4.7M72.1M1.24M
2026-03-316.53%4.7M72.1M1.30M
2026-03-136.08%4.4M72.1M1.18M
2026-02-275.80%4.2M71.9M1.09M
2026-02-136.29%4.5M71.9M953.64K
2026-01-305.72%4.1M71.9M698.07K
2026-01-156.33%4.6M71.9M755.92K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.502.003.001.940.0006.000.000.980-0.0110.000
call1.001.452.451.4110.1030.000.000.938-0.0280.001
call1.501.002.001.427.49231.000.000.900-0.0270.001
call2.001.001.201.022.6101341.000.851-0.0250.001
call2.500.300.700.551.5901,2091.000.756-0.0480.002
call5.000.000.050.022.1681,2900.000.112-0.0110.001
call7.500.000.050.053.50654.000.000.082-0.0130.001
put0.500.000.050.257.7033.000.00-0.022-0.0100.000
put1.000.001.000.008.1660.000.00-0.062-0.0280.001
put1.500.001.000.005.6270.000.00-0.100-0.0270.001
put2.000.000.200.053.9245050.00-0.149-0.0250.001
put2.500.000.650.105.5271030.00-0.244-0.0480.002
put5.001.652.652.306.4892.000.00-0.888-0.0110.001
put7.504.205.200.008.3420.000.00-0.919-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-15SCHEDULE 13GSEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-29SCHEDULE 13GSEC
2026-06-258-KCurrent report2026-06-25SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-25SEC
2026-04-273/A2025-08-24SEC
2026-03-30SCHEDULE 13G/ASEC
2026-03-1810-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-188-KCurrent report2026-03-18SEC
2026-03-098-KCurrent report2026-03-09SEC
2026-03-04SCHEDULE 13GSEC
2026-02-118-KCurrent report2026-02-11SEC
2026-01-308-KCurrent report2026-01-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12101.36K100
2025-11003141

Institutional holders

Manager% owned
BlackRock, Inc.5.02%
RENAISSANCE TECHNOLOGIES LLC1.36%
GEODE CAPITAL MANAGEMENT, LLC1.24%
STATE STREET CORP1.22%
NORTHERN TRUST CORP1.14%
DIMENSIONAL FUND ADVISORS LP0.89%
VANGUARD PORTFOLIO MANAGEMENT LLC0.63%
Stratos Wealth Partners, LTD.0.62%
GOLDMAN SACHS GROUP INC0.59%
MARSHALL WACE, LLP0.56%

Funds

Fund% owned
iShares Russell 2000 ETF2.40%
Fidelity Small Cap Index Fund1.00%
iShares Russell 2000 Growth ETF0.86%
VANGUARD RUSSELL 2000 INDEX FUND0.53%
iShares Micro-Cap ETF0.31%
Dimensional U.S. Small Cap ETF0.27%
WisdomTree Europe Hedged Equity Fund0.24%
Schwab Small-Cap Index Fund0.22%
Ultra-Small Company Market Fund0.22%
Master Small Cap Index Series0.15%

OakChart. PLX. Cached 15 minutes.